I think it was probably related to how much EY could charge for the audit. Also, Reno is a small city and maybe the EY people there had better clients to take. If they left for this type of reason, then there is no reason for the 20% stock drop.
If the dropout rate proves to be high there are a couple of possibilities. 1) run a new trial in combination with some of the newer drugs. 2) run a trial on patients who have failed all available drugs. 3) Ask for FDA approval based on TTP data contingent on starting a new trial designed to take the newer drugs into account. If EXEL was a big company they would start a new trial but they are a small company with limited cash. Maybe they should look to partner the drug with someone who can provide cash.
In the Comet trial the TTP had a p value of 0.0001. Everything now depends on the drop out rate. If a lot of patients dropped out after they progressed to take one of the new prostate cancer drugs approved after the trial was started then the OS results will be completely ruined. The dropout rate is the key.
Is a came changer for Cytokinetics. It will get approved first and therefore become the standard that the CYTK drug has to beat. However, the Novartis drug which is a combination of Diovan and an neprilysin inhibitor, which works completely differently then the CYTK drug. Maybe together they would be a worldbeater.
Short squeeze! , Also, I think the Prostate cancer trial will have positive results. Roche will probably make a buyout offer.
Todays WSJ has a small article saying the Norfolk Southern cancelled the rule and they will talk to the oil shippers and come up with a different plan. No matter what it will cost the ND drillers more to get the oil to market.
Title - Norfolk Southern- Legal Protection Required Against Older Tank Cars
This railroad has become the first big American freight railroad to require its customers to give the railroad legal protection against damages from fires, explosions, or release of hazardous materials.
This applies to all except CPC-1232 cars produced after late 2011. Only 14,000 of the 94,000 current tank cars meet this standard. Now 85% of the tank cars hauling oil don't meet this standard.
Norfolk Southern is not that big in oil but if BNSF or CSX or the US Transportation Dept. follow suit, then look out below.
Since Warren Buffet owns BNSF he has an important decision to make.
I have a technical degree and I did work in an academic cancer research lab for twelve years. I was an early investor in Seattle Genetics, the number one company in antibody drug conjugates. I think the new ADC products from IMMU are very promising. However, you are correct that the company has a great need for cash.
Will they get a good price for IMMU 132 or will somebody pick it up cheap when they run out of cash ?
The Nektar drug seems to have more extensive trial data in regards to heart problems which were not found. The FDA may still ask PCGNX to produce more trial data which will take a long time.
I was a Medarex stock holder and I made a few dollars on the BMY buyout. However, BMY got MEDX very cheaply so if they go after CLDX it won't be for big bucks.
Dr. Goldenberg said the reason they have not concluded a partnership deal for IMMU-132 is that they are waiting for more results (good hopefully) so they can get a better deal.
I made money on MEDX and I am long on IMMU. I hope the 132 data are good. By the way, BMY would be the perfect buyer for IMMU. They have lots of antibodies from MEDX and they would be a good fit for IMMU's dock and lock technology.